Sepracor-Looks very promising Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Harold Engstrom who wrote (4218)	2/17/2000 11:50:00 AM
From: Biomaven	Read Replies (1) of 10280

Harold, Yes, this was indeed an excellent result. There are really two different issues here: 1. Speed of onset. Here nora wins hands down vs. Claritin (loratadine). It probably won't do better than DCL (Claritin II), however - DCL acts much faster than Claritin. 2. Efficacy: This was a surprise. Six hours after dosing, NORA 90 mg produced a significant reduction in TSS compared to LAT and PBO, while NORA 30 mg and LAT produced significant reductions in TSS compared to PBO. (p < .04 for the NORA/LAT [loratadine] comparison) Showing a significant efficacy improvement against the current market leader is quite surprising. It's generally very hard to show efficacy improvements like this when the drug you are trying to beat is already pretty good. Six hours is long enough so that this is definitely showing more than just speed of onset. "Best of breed" is still a definite possibility, although Claritin II and the improved Zyrtec will provide tough competition. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next